AKT-mTORC1 reactivation is the dominant resistance driver for PI3Kβ/AKT inhibitors in PTEN-null breast cancer and can be overcome by combining with Mcl-1 inhibitors
2022 · Oncogene · 30 citations
https://doi.org/10.1038/s41388-022-02482-9
N
Natalie Cureton
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
41
Papers
240
Citations
6
h-index
6
i10-index
Natalie Cureton is an academic researcher from AstraZeneca (United Kingdom). The author has contributed to research in topics: Estrogen and related hormone effects & Advanced Breast Cancer Therapies & Cancer Genomics and Diagnostics. The author has an h-index of 6, co-authored 35 publications.
ORCID: 0000-0002-7795-1483Papers by this author
worksMetabolism-driven in vitro/in vivo disconnect of an oral ERɑ VHL-PROTAC
2024 · Communications Biology · 20 citations
https://doi.org/10.1038/s42003-024-06238-x
Supplementary Data from The Next-Generation Oral Selective Estrogen Receptor Degrader Camizestrant (AZD9833) Suppresses ER<sup>+</sup> Breast Cancer Growth and Overcomes Endocrine and CDK4/6 Inhibitor Resistance
2024 · 0 citations
https://doi.org/10.1158/0008-5472.25370764.v1
Figure 6 from The Next-Generation Oral Selective Estrogen Receptor Degrader Camizestrant (AZD9833) Suppresses ER<sup>+</sup> Breast Cancer Growth and Overcomes Endocrine and CDK4/6 Inhibitor Resistance
2024 · 0 citations
https://doi.org/10.1158/0008-5472.24710674.v2
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat